Caution warranted when defining contraindications in initiating β-blocker therapy--reply

JAMA Intern Med. 2014 Mar;174(3):481-2. doi: 10.1001/jamainternmed.2013.13685.

Authors

Kumar Dharmarajan¹, Harlan M Krumholz²

Affiliations

¹ Division of Cardiology, Columbia University Medical Center, New York, New York2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
² Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut3Section of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut4Robert Wood Johnson Clinical Scholars Program, Section of Cardio.

PMID: 24590098
DOI: 10.1001/jamainternmed.2013.13685

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adrenergic beta-Antagonists*
Contraindications
Drug Utilization / statistics & numerical data*
Heart Failure / drug therapy*
Hospitalization*
Humans

Substances

Adrenergic beta-Antagonists

Grants and funding